K 1.1 mRNA
Alternative Names: K1.1-mRNALatest Information Update: 02 May 2023
Price :
$50 *
At a glance
- Originator Sunshine Biopharma
- Class Antineoplastics; RNA
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Liver cancer
Most Recent Events
- 02 May 2023 Preclinical trials in Liver cancer in Canada (unspecified route)
- 17 Nov 2022 Sunshine Biopharma and Lipid pharmaceuticals agree to co-promote K1.1 in the Canada for Cancer
- 01 Aug 2022 Pharmacodynamics data from a preclinical study in Cancer released by Sunshine Biopharma (Sunshine Biopharma pipeline, August 2022)